Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6-12) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)

NCT05924594 is registered in ClinicalTrials.gov with Cingulate Therapeutics as lead sponsor.

NCT NCT05924594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6-12) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Lead sponsor
Cingulate Therapeutics
Phase
Phase 3
Overall status
Suspended
Start date
July 31, 2023
Completion date
February 28, 2027
Enrollment
45 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, adhd - combined type, attention deficit disorder with hyperactivity, attention deficit hyper activity, attention deficit hyperactivity disorder, attention deficit hyperactivity disorder combined, attention-deficit hyperactivity